ClinicalTrials.gg
CompletedNCT00054600Updated Aug 16, 2017

Safety and Efficacy Study of Photopheresis With UVADEX to Prevent Graft-versus-Host Disease

A Phase 2 interventional study of Methoxsalen and Extracorporeal Photopheresis in Graft-versus-Host Disease, sponsored by Mallinckrodt. Completed at 21 sites in 9 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2017-08-16.

Sponsored by Mallinckrodt · Phase 2, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 454 studies in Graft vs Host Disease with a site in United States — 50 open to participants now, 71 under way, 2 of them phase 3. Graft vs Host Disease · United States.

Enrollment
83rd of 389
60 · median 30
Started
2002
with 16 others
Phase 2
164 of 454
15 open now
Registered
54th of 454
by date

Among the 454 studies in Graft vs Host Disease with a site in United States, this one is the 83rd largest by enrollment of the 389 interventional ones that give a count, is one of 17 that started in 2002, is one of 164 in phase 2, and was the 54th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 149 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

50 of the 454 studies in Graft vs Host Disease with a site in United States are open now. Recruiting first, the newest first:

45 more — sign in →

All 50 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 42 (41%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 454 studies in Graft vs Host Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether Extracorporeal Photopheresis with UVADEX (ECP) prior to bone marrow or peripheral blood stem cell transplantation is effective in the prevention of Graft-versus-Host Disease (GvHD).

Read the detailed description

Approximately 30% of HLA-identical related bone marrow graft recipients and up to 90% of patients receiving bone marrow from unrelated donors develop significant acute GvHD despite the use of prophylactic therapies such as cyclosporine and methotrexate. About half of these patients respond to initial treatment with steroids and require no further treatment. The remainder of these patients are either unresponsive to initial therapy or become steroid-resistant over time. The prognosis in these cases is poor and mortality for patients with steroid-resistant GvHD may be as high as 50%.

ECP is a technique in which peripheral white blood cells are exposed to a photoactivatable compound (UVADEX) administered extracorporeally and ultraviolet A light. After cells are reinfused into the patient, their function is altered, thereby activating mechanisms that allow for further regulation of specific lymphocyte populations. ECP has shown activity in several inflammatory and autoimmune diseases, including scleroderma, rheumatoid arthritis, transplantation rejection, acute and chronic GvHD.

In a previous single-center, open label, single-arm study of 56 patients receiving ECP treatment on two consecutive days and reduced-intensity bone-marrow conditioning prior to bone marrow transplantation from matched or partially matched human donors, the incidence of grade II-IV acute GvHD was less than 10%. This is in contrast to an expected incidence of approximately 40%.

The purpose of this study is to determine the role of ECP, administered pre-transplant, in preventing GvHD when used in conjunction with a standard myeloablative conditioning regimen.

03

Conditions studied

  • Graft-versus-Host Disease

Browse trials for

Keywords

  • Extracorporeal Photopheresis
  • Graft-versus-Host Disease
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with a diagnosis of a of the blood (e.g. leukemia) for which allogeneic bone marrow or peripheral blood stem cell transplantation is a treatment option.
  • Patients who are candidates for a standard allogenic bone marrow transplant or PBSC transplant.
  • Patients must have adequate renal, hepatic, pulmonary and cardiac function to enable the patient to tolerate shifts in the volumes of body fluids associated with extracorporeal photopheresis, as determined by the physician's clinical judgement.
  • Patients must weigh at least 40 kg (88 lbs)

Exclusion criteria

Exclusion Criteria:

  • Patients who have received a prior bone marrow transplant or peripheral blood stem cell transplant.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants

Interventions

06

Study locations

21 sites
  • University of Florida
    Gainesville, Florida 32611, United States
  • University of Chicago
    Chicago, Illinois 60637, United States
  • Tufts New England Medical Center
    Boston, Massachusetts 02111, United States
  • Kansas City Cancer Center
    Kansas City, Missouri 64111, United States
  • Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Texas Transplant
    San Antonio, Texas 78229, United States
  • Royal Brisbane Hospital
    Brisbane, 4006, Australia
  • Peter MacCallum Cancer Institute
    East Melbourne, 8006, Australia
  • Alfred Hospital
    Melbourne, Australia
  • Royal Melbourne Hospital
    Parkville, 3050, Australia
  • St. Vincent's Hospital
    Sydney, 2010, Australia
  • Hospital Azevedo Carvalho
    Jau, Brazil
  • National Cancer Institute
    Rio de Janeiro, Brazil
  • Hemocentro
    Sao Paulo, Brazil
  • Ludwig-Maximiliano Universitaet Muenchen
    Munchen, D-81377, Germany
  • Careggi Hospital
    Florence, 1-50134, Italy
  • San Martino Hospital
    Genova, 16132, Italy
  • Instituto Portugues de Oncologia de Francisco Gentil
    Lisbon, 1099-023, Portugal
  • National Cancer Institute
    Bratislava, Slovakia
  • Ankara University Medical School
    Ankara, 6100, Turkey
  • Hammersmith Hospital
    London, W12 0NN, United Kingdom
07

References and documents

Publications

  • Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, Shlomchik MJ, Emerson SG. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999 Jul 16;285(5426):412-5. doi: 10.1126/science.285.5426.412. PubMed 10411505 ↗
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2002 and a completion of Jun 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 5, 2003
First posted
Feb 6, 2003
Start
Jun 2002
Completion
Jun 2004
Last update
Aug 16, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
No changes since tracking began. The registry record was last updated on Aug 16, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00054600
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Feb 6, 2003
Start date
Jun 2002
Completion
Jun 2004
Last update
Aug 16, 2017
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion